机构:[1]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China昆明医科大学附属第一医院[2]920th Hosp, Peoples Liberat Army Joint Logist Support Force, Kunming, Yunnan, Peoples R China[3]First Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China云南省第一人民医院[4]Second Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China[5]Kunming Med Univ, Affiliated Hosp 2, Kunming, Yunnan, Peoples R China[6]Kunming First Peoples Hosp, Kunming, Yunnan, Peoples R China[7]Yanan Hosp Kunming City, Kunming, Yunnan, Peoples R China[8]Kunming Med Univ, Affiliated Qujing Hosp, Kunming, Yunnan, Peoples R China
第一作者机构:[1]Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
推荐引用方式(GB/T 7714):
Zhang J. Q.,Feng J. G.,Liu T.,et al.Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S673-S673.
APA:
Zhang, J. Q.,Feng, J. G.,Liu, T.,Zhang, X.,Chen, X. B....&Li, S..(2023).Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA:
Zhang, J. Q.,et al."Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S673-S673